Literature DB >> 23701649

Comparison between poor and long-term survivors with glioblastoma: review of an Australian dataset.

Kathryn Maree Field1, Mark Andrew Rosenthal, Merve Yilmaz, Mark Tacey, Kate Drummond.   

Abstract

AIMS: Despite the largely poor prognosis for patients with glioblastoma, 5-year survival approaches 10%. In many circumstances the reasons for discrepant outcomes remain unknown. This retrospective cohort study compared clinical and socio-demographic variables between long-term and poor survivors with glioblastoma.
METHODS: Data from patients with glioblastoma diagnosed from 1998-2010 were accessed from two institutions. The cohort was divided into poor (<6 months), average (6-24 months) and long-term (>24 months) survivors. Clinical and socio-demographic variables were compared.
RESULTS: In total 529 patients were included; 221 (42%) were poor, 260 (49%) average and 48 (9%) long-term survivors. Those surviving >24 months were younger and significantly more likely to be in a higher socioeconomic status group; be of a better performance status; have a frontal lobe tumor; have a craniotomy (rather than a biopsy); have a macroscopic resection; have two or more operations; and participate in a clinical trial. Country of birth, regional versus city residence and public versus private hospital treatment were not associated with differential survival outcomes. An ordered logistic regression analysis showed that age, performance status, extent of resection and clinical trial participation were independently associated with survival.
CONCLUSION: Reassuringly, no statistically significant socio-demographic differences exist when comparing long-term and poor survivors with glioblastoma. Patients surviving more than 2 years were significantly more likely to have participated in a clinical trial. This research could contribute towards informing further research on prognostic variables for patients with glioblastoma.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  glioblastoma; glioma; socio-demographic; socioeconomic; survival

Mesh:

Year:  2013        PMID: 23701649     DOI: 10.1111/ajco.12076

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  14 in total

1.  Disparities in health care determine prognosis in newly diagnosed glioblastoma.

Authors:  Ankush Chandra; Jonathan W Rick; Cecilia Dalle Ore; Darryl Lau; Alan T Nguyen; Diego Carrera; Alexander Bonte; Annette M Molinaro; Philip V Theodosopoulos; Michael W McDermott; Mitchel S Berger; Manish K Aghi
Journal:  Neurosurg Focus       Date:  2018-06       Impact factor: 4.047

2.  Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.

Authors:  Signe Regner Michaelsen; Thomas Urup; Lars Rønn Olsen; Helle Broholm; Ulrik Lassen; Hans Skovgaard Poulsen
Journal:  J Neurooncol       Date:  2018-01-05       Impact factor: 4.130

3.  Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.

Authors:  Katerina Deike; Benedikt Wiestler; Markus Graf; Caroline Reimer; Ralf O Floca; Philipp Bäumer; Philipp Kickingereder; Sabine Heiland; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

4.  HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.

Authors:  Laurence Booth; Jane L Roberts; Adam Conley; Nichola Cruickshanks; Thomas Ridder; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

Review 5.  Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

6.  Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.

Authors:  Laurence Booth; Nichola Cruickshanks; Seyedmehrad Tavallai; Jane L Roberts; Matthew Peery; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

7.  Long-term survivors of glioblastoma: a closer look.

Authors:  Lucy Gately; Sue-Anne McLachlan; Jennifer Philip; Jeremy Ruben; Anthony Dowling
Journal:  J Neurooncol       Date:  2017-10-27       Impact factor: 4.130

8.  Insurance correlates with improved access to care and outcome among glioblastoma patients.

Authors:  Desmond A Brown; Benjamin T Himes; Panagiotis Kerezoudis; Yirengah M Chilinda-Salter; Sanjeet S Grewal; Joshua A Spear; Mohamad Bydon; Terry C Burns; Ian F Parney
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

9.  Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.

Authors:  Theodore Wang; Anthony Pham; Stella Yoo; Frank J Attenello; Richard Jennelle; Naveed Wagle; Eric L Chang; Gabriel Zada
Journal:  World Neurosurg       Date:  2020-01-27       Impact factor: 2.104

10.  Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: a population-based study.

Authors:  Conor S Ryan; Young J Juhn; Harsheen Kaur; Chung-Il Wi; Euijung Ryu; Katherine S King; Daniel H Lachance
Journal:  Neurooncol Pract       Date:  2019-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.